Structure Therapeutics Inc. (NasdaqGM: GPCR)
Health Care · Pharmaceuticals · US
$24.74
-3.15% today · -15.4% 1Y
Structure Therapeutics Inc. (NasdaqGM: GPCR) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.82B and employs 281 people.
Over the last twelve months the share price has lost 15.4%, trading between 25.09 and 94.90.
Tweenvest scores Structure Therapeutics Inc. across four factors: quality 42/100, value 35/100. Its strongest factor is quality.
GPCR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.82B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.22
- Dividend yield
- —
- Beta (5Y)
- -1.37
- 52-week high
- $94.90
- 52-week low
- $25.09
- Avg volume (3M)
- —
- Shares outstanding
- 71.31M
- Employees
- 281
- Next earnings
- —
About Structure Therapeutics Inc.
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
- ISIN
- US86366E1064
- Founded
- 2016
- Listed since
- Feb 3, 2023
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Porton Pharma Solutions Ltd.SZSE: 300363 | $1.90B | CN¥23.68 | -3.58% |
| The United Laboratories International Holdings LimitedSEHK: 3933 | $1.89B | HK$7.52 | +0.07% |
| Trevi Therapeutics, Inc.NasdaqGM: TRVI | $1.88B | $13.19 | 0.00% |
| Beijing Aosaikang Pharmaceutical Co., Ltd.SZSE: 002755 | $1.85B | CN¥13.34 | -1.55% |
| Pfizer LimitedNSEI: PFIZER | $1.80B | Rs3,808.20 | +1.55% |
| Septerna, Inc.NasdaqGM: SEPN | $1.79B | $37.96 | -1.07% |
| Neuren Pharmaceuticals LimitedASX: NEU | $1.79B | AU$20.20 | -0.39% |
| Zhejiang Medicine Co., Ltd.SHSE: 600216 | $1.78B | CN¥12.59 | +1.29% |
Figures last refreshed Oct 11, 2026.